Consequences of Pharmaceutical Fraud Settlements: Off-Label Marketing Continues?
Reporter Susan Todd wrote a fine article in the June 6, 2010 Star –Ledger about off-label marketing. “There are very few companies that haven’t had…
Read More »Pharma 101 – Pharmaceutical Fraud
Pharmaceutical Fraud News & Insight form the Qui Tam and False Claims Act Perspective
Contact FormTag Archives: off label drug marketing
GI Drug Overhyped, Warns FDA
On May 5th, the FDA posted a letter sent to Shire Development, Inc. regarding the marketing of LIALDA, an oral sustained release multimatrix formulation of…
Read More »AstraZeneca Agrees to $520 Million Settlement
Attorney General Eric Holder announced April 27, 2010, that AstraZeneca has agreed to pay $520 million to federal and state taxpayers to settle claims that…
Read More »Biotech Company and Its Top Management Indicted for Illegal Promotion, Making False Statements to the FDA
The Federal Bureau of Investigation (FBI) Boston announced October 28, 2009, that Stryker Biotech and its top management had been indicted for illegal promotion of…
Read More »Grassley Probes into Ghostwriting Practices that May Result in Pharmaceutical Fraud
United States Senator Charles E. Grassley of Iowa has asked eight leading medical journals to describe their ghostwriting policies and practices. The inquiry is part…
Read More »Eli Lilly Pays Record Fine for Off-Label Drug Marketing
Philadelphia, Pennsylvania— Multiple news publications have confirmed that Eli Lilly & Co. will, in the largest United States-imposed criminal fine on an individual company, pay…
Read More »499 Million Bristol-Myers Squibb Agreement to Settle Fraud Charges
The United States Department of Justice has reached a tentative settlement with Bristol-Myers Squibb in the amount of $499 million to settle several investigations involving…
Read More »